NMD Pharma Nears Validation For ClC-1 Inhibition With Lead Program In Myasthenia Gravis

14 Oct 2022

• By Ayisha Sharma

Emerging Company Profile: The Danish firm has achieved proof-of-mechanism for its first-in-class CIC-1 inhibitor asset in myasthenia gravis as it advances a pipeline of transformative therapies for rare neuromuscular disorders.

The Chlorine Ion Channel Is Found Exclusively In Skeletal Muscle • Source: Shutterstock

NMD Pharma has made strides with a new mechanism for the treatment of myasthenia gravis (MG) with its lead program thanks to a unique platform that harnesses ion channel function and electrophysiology of skeletal muscle.

The Danish firm was originally spun out of research conducted by CEO and co-founder Thomas Holm Pedersen on ion channels...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Eolo Pharma Advances In Obesity With Thermogenesis Approach

04 Jul 2025

• By Aakash Babu

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

Immusoft Goes For Cell Therapy Plan ‘B’

26 Feb 2025

• By Alaric DeArment

Emerging Company Profile: CEO Sean Ainsworth spoke with Scrip about how the company is developing B-cell therapies to treat a range of diseases, starting with MPS I.

Sanofi-Backed Resalis Brings MicroRNA To Obesity

29 Nov 2024

• By Elizabeth Cairns

Emerging Company Profile: Resalis will soon start human trials of an oligonucleotide targeting a microRNA that is overexpressed in obese mice, but much remains to be proven in humans.

Volastra Aims To Terminate Cancer Relying On Chromosomal Instability

01 Nov 2024

• By Jessica Merrill

Emerging Company Profile: Volastra is testing two KIF18A inhibitors in early clinical trials in ovarian cancer, backed by investors like Polaris Partners and ARCH Ventures.